Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Club
$299/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Join Canadian Insider Club or Club Ultra to Keep Your Edge

Times are changing, ad revenues are plunging, and Canadian data costs have jumped.

Starting this summer, we will be limiting Canadian company page views to 10 per month for non-members.

Canadian Insider Club members will continue to get Google ad-free and unlimited access to canadianinsider.com.

Join the club to keep your edge! For a limited time, use coupon code SAVE99 to save $99* off a Canadian Insider Club Membership.

*Save $99 on the first year of a new Canadian Insider Club or Canadian Insider Club Ultra membership. Subsequent auto-renewals will be at the standard rate unless canceled. Limited time offer.

Appili Therapeutics Inc. (V:APLI)

Business Focus: Bio Therapeutic Drugs

INK Edge Outlook

Insider Chart - Past 6 Months

INK Ultra Money Free

Insider Filings

Latest 10 SEDI filings for APLI within the last 6 months
Loading...
See all filings within the past 6 months

Company News

Aug 11, 2020 08:57 ET
Appili Therapeutics Receives Eligibility for DTC Trading in the U.S.
Appili Therapeutics Inc. (TSXV: APLI; OTCQX: APLIF) (the Company or Appili), a biopharmaceutical company developing anti-infective drug candidates, today announced that its common shares listed in the United States, under the symbol APLIF, are Depository Trust Company (DTC) eligible. DTC is a subsidiary of the Depository Trust & Clearing Corporation, a U.S. company that manages the electronic clearing and settlement of publicly traded companies. DTC services provide simplification, convenience, and cost benefits for investors and brokers trading Canadian securities in the United States.
Read full article
Aug 10, 2020 07:17 ET
FDA Clears Appili Therapeutics to Expand its Phase 2 Clinical Trial of Favipiravir for the Potential Prevention of COVID-19 at U.S. Long-Term Care Facilities
Appili Therapeutics Inc. (TSXV: APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on anti-infective drug development, today announced that the U.S. Food and Drug Administration (FDA) has granted the Company clearance to proceed after Appili’s filing of an investigational new drug (IND) application for broad-spectrum antiviral favipiravir. Appili is expanding
Read full article
See more news stories

Valuation Ratios

Industry
Sector
Beta
N/A
--
--
Price to Sales - TTM
300.12
16.21
10.04
Price to Book - most recent quarter
6.76
7.84
2.94
Price to Cash Flow per share - TTM
--
2.52
10.75
Price to Free Cash Flow per share - TTM
--
8.64
18.68
See all valuations

Short Report

DateNumber of Shares ShortedNet Change
Jul 31, 202024,1489,086
Jul 15, 202015,062-25,268
Jun 30, 202040,330-82,877
See Short Report

Business Summary

Sector:  Healthcare Industry:  Biotechnology & Medical Research

Appili Therapeutics Inc is a Canada-based pharmaceutical company. The Company is focused on the acquisition and development of treatments targeting infectious disease. The Company is focused on building and advancing adverse portfolio of anti-infective programs. The Company's anti-infective portfolio includes ATI-2307, ATI-1701, ATI-1503, ATI-1501 and Favipiravir. The ATI-2307 is a clinical-stage antifungal candidate in development for severe and difficult-to-treat invasive fungal infections. The ATI-1701 is a vaccine candidate for tularemia. The ATI-1503 is a drug discovery program aimed at generating a class of antibiotics with broad spectrum activity against gram-negative superbugs. The ATI-1501 employs its taste-masked, oral-suspension technology with metronidazole for the patients with difficulty swallowing.

See business summary

 

Twitter

Search (past week) for $APLI.CA APLI.V